The Global Online Sexuality Survey (GOSS): The United States of America in 2011 Chapter II: Phosphodiesterase Inhibitors Utilization among English Speakers

Journal of Sexual Medicine

Volumn 10, Issue 2, 2013, Pages 532-540

  Shaeer, Osama ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Erectile dysfunction; Phosphodiesterase inhibitors; Survey; Treatment; United States of America

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; ARTICLE; DRUG SAFETY; ERECTILE DYSFUNCTION; HABITUATION; HUMAN; INTERNET; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RECREATION; RISK FACTOR; SEXUAL DYSFUNCTION; SEXUALITY; SOCIAL NETWORK; UNITED STATES;

EID: 84873056308     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02972.x     Document Type: Article

References (18)

1. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003;25:2709-23.
2. Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005;2:848-55.
3. Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, Fusco F. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient. J Sex Med 2011;8:3418-32.
4. Raheem AA, Kell P. Patient preference and satisfaction in erectile dysfunction therapy: A comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil. Patient Prefer Adherence 2009;3:99-104.
5. Ljunggren C, Hedelin H, Salomonsson K, Stroberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med 2008;5:469-75.
6. Korkes F, Costa-Matos A, Gasperini R, Reginato PV, Perez MD. Recreational use of PDE5 inhibitors by young healthy men: Recognizing this issue among medical students. J Sex Med 2008;5:2414-8.
7. Bechara A, Casabe A, De Bonis W, Helien A, Bertolino MV. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. J Sex Med 2010;7:3736-42.
8. Shaeer O, Shaeer K. The Global Online Sexuality Survey (GOSS): Erectile dysfunction among Arabic-speaking internet users in the Middle East. J Sex Med 2011;8:2152-63.
9. Shaeer O, Shaeer E, Shaeer K. The Global Online Sexuality Survey (GOSS): Female Sexual Dysfunction among Internet Users in the Reproductive Age Group in the Middle East. J Sex Med 2012;9:411-24.
10. Shaeer O, Shaeer K. The Global Online Sexuality Survey (GOSS): Ejaculatory Function, Penile Anatomy, and Contraceptive Usage among Arabic-Speaking Internet Users in the Middle East. J Sex Med 2011;9:425-33.
11. Ahmad O, Boschi-Pinto C, Lopez A, Murray C, Lozano R, Inoue M. Age standardization of rates: A new who standard, Gpe Discussion Paper Series: No.31 EIP/GPE/EBD World Health Organization. 2001.
12. Shaeer O, Sheer K. The Global Online Sexuality Survey (GOSS): The United States of America in 2011 chapter I: erectile dysfunction among English-speakers. J Sex Med 2012; doi: 10.1111/j.1743-6109.2012.02976.x.
13. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-26.
14. Symonds T, Perelman MA, Althof S, Giuliano F, Martin M, May K, Abraham L, Crossland A, Morris M. Development and validation of a premature ejaculation diagnostic tool. Eur Urol 2007;52:565-73.
15. Schnetzler G, Banks I, Kirby M, Zou KH, Symonds T. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. J Sex Med 2010;7:1237-46.
16. Jackson G, Arver S, Banks I, Stecher VJ. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks. Int J Clin Pract 2012;66:241-50.
17. Aronson JK. From prescription-only to over-the-counter medicines ("PoM to P"): Time for an intermediate category. Br Med Bull 2009;90:63-9.
18. Shabsigh R, Kaufman J, Magee M, Creanga D, Russell D, Budhwani M. Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction. BMC Urol 2010;10:18.